Drugs & TargetsFree Kisqali gets FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor March 17, 2017Vol.43 No.11
Drugs & TargetsFree Keytruda gets accelerated approval for classical Hodgkin lymphoma March 17, 2017Vol.43 No.11
Drugs & TargetsFree FDA extends Keytruda PDUFA date for microsatellite instability-high cancer March 17, 2017Vol.43 No.11
Drugs & TargetsFree Mylan announces settlement, license deals with Genentech and Roche on Herceptin March 17, 2017Vol.43 No.11
Drugs & TargetsFree Oncoceutics expands DRD2 research collaborations with NIH March 17, 2017Vol.43 No.11
Drugs & Targets NICE recommends Vectibix for previously untreated metastatic colorectal cancer March 10, 2017Vol.43 No.10
Drugs & Targets EnGeneIC receives Orphan designation for its technology in glioblastoma multiforme March 10, 2017Vol.43 No.10
Drugs & Targets German Community of Gynecological Oncology acknowledges MammaPrint as having Level 1A clinical evidence March 10, 2017Vol.43 No.10
Drugs & TargetsFree FDA approves Xermelo as first and only treatment for carcinoid syndrome diarrhea March 03, 2017Vol.43 No.09
Drugs & TargetsFree FDA Accepts avelumab BLA for Priority Review for urothelial carcinoma March 03, 2017Vol.43 No.09
